OriCell Therapeutics

1.1 Identity, business model, and development stage

OriCell is described by company and independent sources as a Shanghai-based clinical-stage biotechnology company developing cell therapies for cancer. The business remains a development-stage model rather than a demonstrated recurring-revenue operation: retained evidence identifies no approved product, recognized revenue, or verified customer count. The lead program is Ori-C101, a GPC3-targeted autologous CAR-T candidate for advanced hepatocellular carcinoma, while OriCAR-017 targets GPRC5D in relapsed or refractory multiple myeloma. Public descriptions also identify antibody discovery, CAR engineering, and manufacturing capabilities. These assets support a coherent platform narrative, but clinical, regulatory, manufacturing, and financing execution still determine enterprise value.[CO001, CO002, CO003, CO004, CO005, CO006]

1.2 Leadership, founders, and governance

A 2026 PharmaBoardroom interview identifies Helen Yang and Peter He as founders and describes Peter He as chief scientific officer. OriCell's September 2026 media-center notice instead identifies Huanfeng Yang as co-founder, chairman, and former chief executive, and says Feng Guo became chief executive for group business and operations while Huanfeng Yang remained chairperson and president. The retained sources do not establish whether Helen Yang and Huanfeng Yang are alternative names for the same person. That ambiguity should not be resolved by assumption. The public record also lacks a complete board roster, voting structure, committee mandates, and succession plan, making leadership identity, authority boundaries, and key-person dependence priority diligence items.[CO007, CO008, CO009]

1.3 Financing history and stakeholder map

OriCell announced a pre-IPO financing above $110 million in April 2026 after earlier reported rounds, including a $125 million Series B in 2022, a $45 million B1 in 2023, and a $70 million Series C1 closing in January 2026. The latest syndicate included Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital. Tracxn reports $350 million in total funding across four rounds, but AllSci notes that the April announcement did not disclose previous funding totals. The figures therefore describe financing activity, not cash currently available, and do not establish valuation, dilution, liquidation preferences, burn, or runway.[CO010, CO011, CO012, CO013, CO014, CO015]

1.4 Milestones and underwriting limits

The 2026 record shows execution momentum: OriCell announced Series C1 and pre-IPO financings, reported Ori-C101 clinical data, received company-reported NMPA clearance for a confirmatory Phase II trial, and changed chief executive leadership. Those events strengthen the case that the company is active and advancing, but they do not substitute for primary regulatory letters, audited accounts, or independently verified trial records. The solid-tumor modality also carries category-level constraints. A 2026 technical review identifies inadequate tumor infiltration, immunosuppressive microenvironments, and metabolic obstacles as barriers to CAR-T efficacy in solid tumors. The appropriate underwriting posture is evidence-positive but conditional on primary clinical, regulatory, governance, and cash documentation.[CO005, CO008, CO010, CO012, CO016]

1.5 Exhibits

2.1 Market boundary and demand ceiling

OriCell's relevant market is narrower than oncology overall. Its disclosed lead programs focus on GPC3-targeted autologous CAR-T for advanced hepatocellular carcinoma and GPRC5D-targeted CAR-T for relapsed or refractory multiple myeloma. IARC and the American Cancer Society estimate 20.6 million new cancer cases and 9.8 million cancer deaths worldwide in 2024, but that denominator spans 34 cancer types in 186 countries and cannot be treated as OriCell's addressable population. The applicable pool must be filtered by indication, target expression, line of therapy, clinical eligibility, geography, referral access, and payer coverage. Status-quo substitutes include approved systemic therapies, transplant and other cell therapies, clinical trials, and supportive care; non-target cancers and patients unable to reach specialist centers are outside the practical boundary.[CM001, CM003, CM004, CM005, CM006]

2.2 Evidence-constrained sizing

Three lenses are supportable, but none is a revenue TAM. First, IARC's epidemiology gives a global demand ceiling: 20.6 million new cases in 2024, with incidence projected to reach 34.4 million by 2050, a 67% increase. Second, indication proxies narrow the lens: liver cancer represented 7.5% of global cancer deaths in the 2024 estimate, while the American Cancer Society expects about 36,000 new multiple-myeloma cases in the United States in 2026. Third, CARsgen's reported Chinese approval of satri-cel for a biomarker-defined, later-line gastric or gastroesophageal-junction population demonstrates a solid-tumor CAR-T regulatory precedent. It does not establish OriCell's efficacy, eligible population, price, reimbursement, capacity, or share. A bottom-up SAM and SOM remain unavailable because the allocated evidence supplies none of those company-specific denominators.[CM001, CM002, CM003, CM004, CM008, CM009, CM016]

2.3 Buyer, user, payer, and adoption path

The patient is the beneficiary and the oncologist or hematologist is the clinical decision maker, but treatment delivery depends on specialist hospitals, trial networks, cell-therapy operations, and payers. Autologous CAR-T requires referral, patient selection, cell collection, manufacturing, release testing, lymphodepletion, infusion, and monitoring, making hospital capacity and reimbursement as important as physician demand. OriCell says its OnGo platform is intended for rapid, scalable manufacturing, yet the public evidence does not disclose cycle-time distributions, release success, remanufacture rates, site throughput, cost of goods, product price, or coverage. Positive pivotal data, approval, center readiness, and a reimbursed pathway would trigger adoption. Tumor heterogeneity, poor T-cell infiltration, the immunosuppressive microenvironment, toxicity management, logistics, and durability requirements can delay or restrict it.[CM010, CM012, CM014, CM015]

2.4 Drivers, constraints, and valuation relevance

The opportunity has real demand and financing signals: global cancer incidence is projected to rise, a solid-tumor CAR-T has reportedly secured a defined approval, and OriCell's April 2026 financing exceeded $110 million for clinical expansion and platform development. These signals indicate capital availability and sector interest, not product demand or commercial validation. The principal disconfirming evidence is technological and operational. Independent technical literature describes trafficking, infiltration, immunosuppression, and safety as persistent HCC CAR-T barriers, while BioPharm International characterizes in-vivo CAR-T as largely preclinical across the industry. Underwriting should therefore require target-positive epidemiology by geography, protocol-to-label filters, center capacity, manufacturing yields and cycle times, payer coverage, pricing, and competitive-share sensitivities. Until those inputs exist, market size should contribute option value rather than a precise revenue or valuation bridge.[CM002, CM008, CM010, CM011, CM013, CM014, CM016]

2.5 Exhibits

3.1 Competitive landscape and strategic position

OriCell's lead position is in a difficult frontier rather than an uncontested niche. MedCity News describes Ori-C101 as an autologous GPC3 CAR-T for advanced hepatocellular carcinoma and notes that solid tumors remain difficult because the tumor microenvironment is immunosuppressive. The same account identifies Eureka Therapeutics, AstraZeneca's AZD7003, and Zymeworks' ZW251 as competing GPC3 approaches, while Bristol Myers Squibb is pursuing a dual-targeting GPRC5D/BCMA CAR-T in multiple myeloma. This means OriCell faces direct target competition in liver cancer, modality substitution from antibody-drug conjugates, and better-capitalized incumbents in hematology. The relevant status quo is continued standard systemic oncology treatment or later-line hematology therapy, not simply another CAR-T vendor.[CP001, CP002, CP003, CP004, CP016]

3.2 Capability, distribution, and switching comparison

The public comparison is strongest on target, modality, stage, and manufacturing approach, and weakest on realized price, customer access, and comparative quality. OriCell describes platforms spanning antibody discovery, T-cell enhancement, and rapid manufacturing; MedCity News reports that the company is also developing in-vivo cell therapies intended to avoid the multiple steps of autologous treatment. Established products illustrate the buyer's operational tradeoff: CARVYKTI is a one-time infusion but its manufacturer describes a five-step process taking around two to three months, while ABECMA describes blood collection, cell creation, administration, and monitoring. OriCell may differentiate through solid-tumor biology and faster manufacturing, but public evidence does not establish release rates, turnaround distributions, site breadth, reimbursement, or a switching cost that would protect it after competing products become available.[CP005, CP006, CP007, CP008, CP009, CP015]

3.3 Moat durability and displacement risks

OriCell's potential moat is a combination of target-specific clinical data, integrated discovery-to-manufacturing capabilities, and a pipeline spanning solid tumors, hematologic malignancies, and in-vivo approaches. Its durability is still conditional. A 2026 competitive landscape review characterizes autologous manufacturing bottlenecks, antigen escape, allogeneic persistence, solid-tumor biology, and treatment price as structural risks across the field; it also reports that no allogeneic CAR-T product had been approved in its review. For OriCell, the key displacement tests are whether GPC3 responses reproduce in pivotal testing, whether competitors with global development and manufacturing infrastructure move faster, and whether off-the-shelf or rapid-production products reduce the burden of patient-specific manufacturing. The evidence supports a research-more posture rather than a conclusion that the moat is established.[CP010, CP011, CP012, CP013, CP014]

3.4 Exhibits

4.1 Revenue model and monetization visibility

OriCell's public materials describe a clinical-stage oncology and immunology biotechnology company developing autologous CAR-T therapies, rather than a commercial product company with disclosed recurring revenue. The official site identifies Ori-C101 and OriCAR-017 as clinical programs and describes platform capabilities, but it does not provide list prices, contracts, product sales, revenue, or realized reimbursement. A third-party private-company profile labels the revenue model as licensing, while another profile describes the company as B2B; neither provides a contract, royalty rate, milestone schedule, or recognized revenue. The financially supportable conclusion is therefore not that licensing revenue exists, but that a licensing pathway is plausible and unverified. The model is currently dependent on financing and future clinical or partnering milestones, not public operating cash flow.[CI001, CI002, CI003, CI004]

4.2 GTM motion, cost structure, and unit economics

The assigned sources provide no customer acquisition cost, sales cycle, payback, gross margin, contribution margin, cost of goods sold, working-capital schedule, or capex disclosure. That absence is material because autologous cell therapy economics depend on patient acquisition, treatment-center access, manufacturing release, logistics, and quality-control costs; platform descriptions alone do not quantify any of those drivers. OriCell says proceeds are intended for global clinical development, manufacturing-capability expansion, and capital-market milestones, while earlier financing was directed toward U.S. clinical development. Those uses indicate a research, clinical, and manufacturing cost base, but they do not establish burn or unit economics. Any scenario should keep realized pricing, treatment cost, batch failure or remanufacture rates, and site economics as unavailable inputs rather than substituting public list prices or peer-company margins.[CI005, CI006, CI007, CI008]

4.3 Capital adequacy and financing dependency

Financing is the clearest public financial signal. The assigned sources report an April 2026 pre-IPO round in excess of $110 million, a January 2026 Series C1 initial closing of $70 million, a February 2023 Series B1 round of $45 million, and a July or August 2022 Series B reported at more than $120 million or $125 million depending on the source. These are financing proceeds, not cash on hand, and the sources do not disclose post-money valuation, current balance, monthly burn, runway, debt, or liquidation preferences. The proceeds are described as supporting global clinical development and manufacturing expansion, so capital needs remain milestone-dependent. The round chronology supports improved funding capacity but cannot establish solvency through the next value-creating milestone without management accounts and a cash forecast.[CI009, CI010, CI011, CI012]

4.4 Financial underwriting verdict and diligence blockers

OriCell's financial profile is investable only as a private, clinical-stage financing case rather than as an operating-revenue underwriting. Evidence supports a substantial investor syndicate and continued pipeline progression, including a confirmatory Phase II path for Ori-C101 and global development for OriCAR-017, but those milestones are not revenue recognition events. The strongest positive is access to fresh capital; the strongest negative is that public sources do not provide the cash bridge needed to map that capital to runway, manufacturing scale, or commercialization readiness. The evidence also contains inconsistent aggregate-funding and round labels across data vendors, and one source reports a 25-person employee count while other sources do not provide a current headcount. Before underwriting price or return, diligence should obtain audited or management financials, the current cap table and terms, cash and burn by function, manufacturing cost and release data, and any licensing or commercial contracts.[CI013, CI014, CI015, CI016]

5.1 Product portfolio and clinical maturity

OriCell's product is an oncology cell-therapy portfolio rather than a single commercial SKU. Independent profile material describes CAR-T, cell-therapy, and gene-therapy modalities, while Synapse lists 19 CAR-T programs and projects spanning discovery through Phase 2. The most visible assets are Ori-C101/ORIC-101 for GPC3-positive hepatocellular carcinoma and OriCAR-017 for multiple myeloma. OriCAR-017 is described by an investor source as a GPRC5D CAR-T program at the IND-enabling stage in the United States and China, whereas later coverage describes it as a Phase 1/2 China trial; the differing descriptions reinforce the need to verify the current registry and readout. An NCI registry record provides an external GPC3-targeted CAR-T workflow benchmark in advanced GPC3-expressing solid tumors, but it is not an OriCell-sponsored study and does not establish OriCell efficacy or commercialization readiness.[CE001, CE002, CE003, CE004]

5.2 Technology and operating architecture

The disclosed architecture is an integrated discovery-to-manufacturing workflow. Gosset identifies OriAb, OriCAR, OriTIL, and OriUCAR as proprietary platforms intended to engineer next-generation CAR-T therapies, and says the company has capabilities spanning discovery, clinical development, and GMP-compliant manufacturing. A financing announcement gives a more specific three-part description: OriAb for antibody screening and engineering, OriArmoring for functional enhancement, and OnGo for rapid CMC manufacturing. These descriptions indicate where value may accrue—target selection, activity in the solid-tumor microenvironment, and production speed—but they do not provide release-rate distributions, batch-failure rates, turnaround times, persistence data, or head-to-head comparisons. The engineering and manufacturing claims should therefore be treated as company-issued or secondary summaries until supported by technical protocols and audited quality data.[CE005, CE006, CE007, CE008]

5.3 Clinical workflow and differentiation

The customer-facing workflow is a high-risk clinical development process: identify a tumor antigen, design and manufacture an autologous cell product, administer it to eligible patients, and generate controlled evidence through staged trials. Ori-C101 is aimed at GPC3, a target emphasized for liver cancer, while OriCAR-017 is aimed at GPRC5D in multiple myeloma. The differentiator is consequently a combination of target selection, cell engineering, immune-microenvironment functionality, and manufacturing execution rather than a proven software-like distribution advantage. Coverage reports a small 2025 ASCO study in which the company said six of ten treated patients responded and nine achieved disease control; that is a company statement reported by BioPharma Dive, not an independently verified efficacy benchmark. Public materials also mention secreted, rapid-production, and in-vivo CAR-T modalities, but do not disclose their clinical maturity.[CE009, CE010, CE011, CE012]

5.4 Maturity, controls, and diligence blockers

Technical maturity is uneven across the portfolio. Clinical-stage programs and a registered GPC3 study show that OriCell has moved beyond discovery, while Synapse also lists discovery, preclinical, IND, and early clinical projects. Regulatory and quality controls are not fully visible in the assigned public evidence: the sources mention IND clearances or approvals and GMP-compliant manufacturing, but do not disclose inspection outcomes, comparability packages, validated release specifications, cybersecurity or privacy controls, or post-treatment safety monitoring. The patent evidence is similarly incomplete. RTW reports more than 100 invention patent applications and 10 granted patents, while WIPO PATENTSCOPE confirms a searchable global collection but does not identify an OriCell portfolio in the fetched landing page. The key technical diligence work is to reconcile asset names and phases, inspect trial-level safety and durability, validate CMC reproducibility, and complete freedom-to-operate analysis around GPC3, GPRC5D, armored constructs, and in-vivo extensions.[CE013, CE014, CE015, CE016]

5.5 Exhibits

6.1 Buyer, user, and payer segments

OriCell is a clinical-stage biotechnology company, so its current “customer” system is primarily a clinical-development network: patients are treatment users, investigators and hospitals are deployment sites, and the company and its investors fund development. A public company profile describes the business as B2B with a licensing revenue model, but that profile is not a financial filing and does not identify a signed licensee or payer. The public record instead names a multi-center OriCAR-017 study in China and a separate United States study described as the first U.S. clinical study for the company. This supports a site-and-patient adoption map, not proof of product sales. Geographic expansion is visible in the company's global-development statements, while the commercial channel, reimbursement path, contract economics, and customer decision maker remain unresolved.[CU001, CU002, CU003, CU004]

6.2 Adoption and clinical proof trajectory

The strongest measurable adoption proxies are trial enrollment, study status, clinical readouts, and progression from investigator-initiated work to registrational development. The OriCAR-017 registry reports a recruiting Phase I/II, open-label, multi-center study with estimated enrollment of 83 adults, while the U.S. registry description identifies a first U.S. study evaluating safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy. For Ori-C101, a June 2026 evidence record reports 18 efficacy-evaluable late-line HCC patients and an overall response rate of 50%, rising to 66.7% at the recommended Phase 2 dose; these are clinical endpoints, not customer retention or commercial utilization. The 2026 financing release says both Phase I IIT and Phase I IND studies were completed and pivotal work was next, indicating development progression but not launch readiness.[CU005, CU006, CU007, CU008, CU009]

6.3 Named-site proof and reference quality

Named clinical sites provide stronger evidence than an undifferentiated logo list, but they still represent trial participation rather than paid production deployment. The OriCAR-017 registry lists Beijing GoBroad Hospital, The First Affiliated Hospital with Nanjing Medical University, Tongji Hospital of Tongji University, Union Hospital Tongji Medical College, and The First Affiliated Hospital of Zhejiang University; the registry marks some sites recruiting and others not yet recruiting. The U.S. study record separately identifies a first U.S. clinical study but does not disclose a commercial customer or outcome. OriCell's financing and investor communications describe global expansion and partnerships as objectives, while the available evidence does not disclose site contracts, paid-access terms, repeat utilization, or patient-level follow-up by site. Reference quality is therefore medium for clinical-network breadth and low for commercial durability.[CU010, CU011, CU012, CU013]

6.4 Retention, expansion, and concentration risks

No assigned source reports net revenue retention, gross retention, churn, renewal rates, contract duration, revenue by customer, or concentration of active sites. The clinical registry's recruiting and not-yet-recruiting labels show that the network is still operationally developing, but they cannot establish repeat purchase or expansion. The public evidence also does not quantify manufacturing turnaround by site, referral conversion, reimbursement, or the share of enrollment supplied by any one investigator, hospital, geography, or partner. Consequently, customer durability should be treated as unproven and concentration as an open diligence risk rather than as absent risk. The next diligence step is a site-level schedule showing contracted sites, activated sites, screened and dosed patients, manufacturing failures, follow-up completion, and economics by program and geography.[CU014, CU015, CU016]

6.5 Exhibits

7.1 Ranked residual risk

The evidence supports a high-risk underwriting posture rather than a conclusion that an adverse event has occurred. Ori-C101 is still moving from investigator-led and early registrational work toward pivotal development, while a financing article explicitly warns that clinical timelines and regulatory outcomes remain uncertain. The company also must turn claimed rapid manufacturing and integrated GMP capability into repeatable release performance at larger scale. Capital risk ranks alongside these technical risks because three current databases report materially different cumulative funding totals, and none reports cash, monthly burn, or milestone-adjusted runway. The heatmap therefore scores residual exposure from disclosed stage and evidence gaps, not from an assumption that a failure or incident has already happened.[CR003, CR004, CR005, CR006, CR007, CR009, CR010, CR014, CR015]

7.2 Regulatory, clinical, and legal exposure

The core legal-regulatory issue is transition risk. Independent summaries report that Ori-C101 has completed investigator-initiated work and a registrational Phase I study, with pivotal trials still ahead. OriCAR-017 has useful regulatory signals, including US orphan and Fast Track designations and IND permissions in China and the United States, but those statuses are not approvals to market. The public record also describes more than 100 patent applications but only 10 grants as of 2023; application volume does not establish claim quality or freedom to operate. The USPTO provides a public PTAB search route, yet a company-specific docket, patent-family map, licensing schedule, and counsel opinion remain necessary before underwriting defensibility.[CR006, CR007, CR008, CR011, CR013]

7.3 Manufacturing, quality, and portfolio execution

Manufacturing is both a claimed differentiator and an unverified operational dependency. Sources describe integrated GMP-compliant manufacturing, planned expansion of manufacturing capability, and a claimed process of under seven days. None of the retained evidence reports batch-release success, vein-to-vein turnaround distributions, remanufacture frequency, capacity utilization, comparability results, or named critical suppliers. Those omissions matter because pivotal execution requires consistent CMC performance, not merely platform descriptions. A third-party pipeline snapshot also shows programs spread across discovery, preclinical, IND, and clinical categories, increasing prioritization demands. There is likewise no retained security or privacy-control evidence; this is a diligence gap, not proof that a breach or compliance failure occurred.[CR002, CR009, CR010, CR012, CR015, CR016]

7.4 Capital and dependency kill criteria

The April 2026 round was reported at more than $110 million and was earmarked for clinical development, manufacturing expansion, global activity, and capital-markets preparation. That funding is supportive, but capital raised is not cash available. Indexed, Tracxn, and Multiples report cumulative totals of $364 million, $350 million, and $419 million respectively, with different round counts, so the aggregate cannot be used as a precise liquidity proxy. The investment thesis should break if audited cash and committed capital do not cover the next clinical and CMC milestones with a reasonable contingency, if pivotal timing slips without a funded recovery plan, if release performance misses agreed thresholds, or if FTO diligence reveals blocking claims without a credible license or design-around.[CR002, CR003, CR004, CR005, CR014, CR015, CR016]

7.5 Exhibits

8.1 Investment view and entry discipline

OriCell's investable case is a financing-supported clinical platform rather than a revenue-underwritten business. FinSMEs and AllSci describe a $110M pre-IPO financing announced in April 2026, while QuotedData documents a prior $45M Series B-1 round and Multiples reports an April 2026 $110M round plus an earlier $70M round. That sequence indicates access to specialist and strategic capital, but it does not disclose the price, post-money valuation, security, dilution, or preferences. The operating proof is also pre-commercial: the pipeline is led by Ori-C101 in hepatocellular carcinoma and OriCAR-017 in multiple myeloma, with other programs at early phases. Accordingly, a research-more recommendation is price-sensitive: a disclosed round at a disciplined valuation could improve the call, while a high implied value without pivotal efficacy, manufacturing release data, or runway evidence would weaken it.[CV001, CV002, CV003, CV004, CV005]

8.2 Thesis, anti-thesis, and comparable signals

The thesis rests on three observable signals: repeated institutional financing, a diversified CAR-T pipeline, and a sector exit environment that can reward differentiated oncology assets. Gosset describes Ori-C101 as a GPC3-targeted lead program and an integrated discovery-to-manufacturing model; Synapse lists 31 pipeline assets across discovery through Phase 2; and EY reports that late-stage VC and oncology M&A remained active in 2025 and early 2026. The anti-thesis is equally concrete. Public datasets disagree on cumulative funding ($350M across four rounds at Tracxn versus $419M across eight rounds at Multiples), and no assigned source provides OriCell's revenue, cash, burn, ownership, or price-bearing terms. Gracell's $1.2B acquisition is a useful transaction reference for a public clinical-stage cell-therapy company with specified consideration and a milestone-linked contingent value right, not a directly comparable OriCell valuation. These signals support optionality, not a precise mark.[CV006, CV007, CV008, CV009, CV010, CV011]

8.3 Scenarios, exit readiness, and diligence asks

Scenario ranges should be treated as decision rules, not forecasts, because the assigned evidence lacks a company valuation and commercial financials. The bull case requires pivotal clinical evidence, reproducible manufacturing, a price-bearing financing at a supportable step-up, and credible IPO or strategic-partner readiness. The base case is continued private financing while Ori-C101 and OriCAR-017 generate additional clinical evidence, with valuation held at unknown until terms and runway are disclosed. The bear case is a down-round or extended private period caused by weak efficacy, manufacturing constraints, regulatory delay, or capital-market compression. EY's finding that the IPO market declined about 47% in 2025 and that many biotechs faced a liquidity trap supports using financing access as a monitored risk rather than assuming an exit. The next diligence package should include the signed financing term sheet, fully diluted cap table, preference stack, cash and monthly burn, runway to the next milestone, program budgets, manufacturing release and turnaround metrics, and updated clinical readouts.[CV012, CV013, CV014]

8.4 Decision rule

The current recommendation is research-more with low-to-medium confidence in the valuation conclusion and high risk. The evidence is sufficient to establish financing momentum and a potentially valuable pipeline, but not sufficient to establish investor returns, a target entry price, or downside protection. An investor should advance only if terms-level diligence closes the valuation and liquidity gaps and if the next clinical milestone improves the probability of a strategic or public-market exit. A thesis-break trigger is a financing that materially dilutes existing holders without a corresponding clinical or regulatory step-up, a failure to reproduce lead-program efficacy, or a runway shortfall before the next value-creating milestone.[CV003, CV009, CV012, CV014]

8.5 Exhibits